ArticleOncogene2025

A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer.

Sayanika Dutta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.